C-reactive Protein Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Assay Type (Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay, Others), By Detection Range (hs-CRP, Conventional CRP, cCRP), By Disease Area (Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus, Others), By End-Use Industry (Hospitals & Clinics, Laboratories, Assisted Living Healthcare Facilities, Homecare, Others), By Region & Competition, 2020-2030F

Market Overview

Global C-reactive Protein Testing Market was valued at USD 1680.20 Million in 2024 and is anticipated to project steady growth in the forecast period with a CAGR of 2.10% through 2030. C-reactive protein (CRP) testing is a diagnostic laboratory test that measures CRP levels in the blood, a biomarker of inflammation produced by the liver. It plays a crucial role in assessing the body's response to infections, injuries, and chronic inflammatory conditions. Physicians widely use CRP testing for diagnosing and monitoring infectious diseases, autoimmune disorders, cardiovascular conditions, and post-surgical inflammation. The test results, measured in milligrams per liter (mg/L), help determine the severity and progression of inflammation, aiding in early detection and disease management.

The global CRP testing market is expanding due to multiple factors, including the rising prevalence of chronic diseases, technological advancements, and the growing adoption of precision medicine. The increasing incidence of cardiovascular diseases, rheumatoid arthritis, diabetes, and autoimmune disorders has driven the demand for CRP testing as an essential diagnostic tool. Advancements in high-sensitivity CRP (hs-CRP) assays, AI-driven diagnostics, and automated laboratory testing have significantly improved test accuracy and efficiency. Additionally, the expansion of telemedicine and home-based healthcare is fueling demand for portable, point-of-care, and self-testing CRP devices, improving accessibility in both developed and emerging markets.

The future of the CRP testing market looks promising, with continued integration of AI and digital health solutions enhancing test interpretation and risk assessment. Personalized medicine is also gaining traction, with CRP testing being incorporated into tailored treatment plans to optimize disease management based on individual inflammatory markers. Furthermore, government healthcare initiatives and favorable reimbursement policies are expected to support greater adoption of CRP testing worldwide. With ongoing innovations, the rising burden of inflammatory diseases, and a shift toward preventive healthcare, the CRP testing market is set for sustained global growth in the coming years.

Key Market Drivers

Growing Incidence of Inflammatory and Infectious Diseases

The rising prevalence of inflammatory and infectious diseases is a significant factor driving the expansion of the global C-reactive protein (CRP) testing market. CRP testing is widely utilized as a diagnostic and prognostic tool for detecting infections, autoimmune disorders, cardiovascular diseases, and other inflammatory conditions. As the incidence of these diseases continues to increase worldwide, the demand for CRP testing is expected to surge. CRP testing plays a critical role in diagnosing and monitoring chronic inflammatory diseases, such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and lupus, as well as acute inflammatory conditions, including sepsis and pneumonia. Globally, 18 million people are living with rheumatoid arthritis (RA). Women account for approximately 70% of RA cases, and 55% of those affected are over the age of 55. Additionally, 13 million individuals experience moderate to severe RA, where rehabilitation could significantly improve their quality of life. The global rise in autoimmune and inflammatory disorders—attributable to genetic predisposition, environmental triggers, and lifestyle factors—has led to greater adoption of CRP testing in clinical settings.

In 2023, tuberculosis (TB) claimed 1.25 million lives globally, including 161,000 individuals living with HIV. After three years of being surpassed by COVID-19, TB has likely regained its position as the leading cause of death from a single infectious agent worldwide. It remains the top cause of death among people with HIV and a major contributor to antimicrobial resistance-related fatalities. An estimated 10.8 million people were diagnosed with TB in 2023, including 6.0 million men, 3.6 million women, and 1.3 million children. TB affects all countries and age groups, yet it is both curable and preventable with timely intervention and treatment. The increasing prevalence of infectious diseases, including bacterial, viral, and fungal infections, has heightened the demand for CRP testing. Respiratory infections (such as pneumonia and COVID-19), bloodstream infections, and urinary tract infections often trigger an inflammatory response, leading to elevated CRP levels. Healthcare providers rely on CRP testing to assess the severity of infections, differentiate between bacterial and viral causes, and guide antibiotic therapy decisions.

The rising demand for rapid and accessible diagnostic solutions has fueled the adoption of point-of-care (POC) CRP testing devices. Point-of-care testing in healthcare practices can significantly reduce the need for follow-up visits and calls. A study found that providing routine tests—hemoglobin A1c, hemoglobin, and lipid panels—on-site led to a 21% decrease in tests ordered per patient, an 89% reduction in follow-up calls, and a 61% decline in patient follow-up visits. These portable and user-friendly diagnostic tools enable physicians to obtain quick CRP results, facilitating timely medical interventions. The expansion of POC testing, particularly in primary healthcare centers, rural clinics, and home healthcare settings, is accelerating market growth. The COVID-19 pandemic significantly increased the demand for CRP testing, as CRP levels were widely used as a biomarker for disease severity. In 2020 and 2021, COVID-19 emerged as one of the top three leading causes of death worldwide, claiming 4.1 million lives in 2020 and 8.8 million in 2021. It was the leading cause of death in the Americas during both years and ranked among the top five causes of death in all regions, except for the African and Western Pacific regions. Hospitals and diagnostic laboratories integrated CRP tests into their routine COVID-19 assessments, leading to higher test volumes and technological advancements in CRP testing methods.

Increasing Awareness of Preventive Healthcare

The increasing awareness of preventive healthcare has a significant impact on driving the growth of the global C-reactive protein (CRP) testing market. Preventive healthcare focuses on identifying health issues at an early stage, even before symptoms become apparent. CRP testing serves as a valuable tool in this context by detecting low-grade inflammation that might not be clinically evident yet. Early detection of inflammation through CRP testing enables timely intervention and management, potentially preventing the progression of underlying diseases. Preventive healthcare often involves assessing an individual's risk of developing certain diseases. CRP testing can contribute to risk stratification by providing information about a person's inflammation levels. Elevated CRP levels are associated with an increased risk of conditions such as cardiovascular diseases, making CRP testing a valuable component of risk assessment protocols. The awareness of preventive healthcare promotes the idea of personalized health plans tailored to an individual's specific risk factors and health needs. CRP testing adds an objective biomarker to guide these personalized plans, helping healthcare providers design interventions and lifestyle modifications that address inflammation-related risks. Preventive healthcare often emphasizes lifestyle modifications to promote better health outcomes. CRP testing results can serve as a tangible marker that motivates individuals to make healthier choices, such as improving their diet, increasing physical activity, and quitting smoking. The availability of CRP testing supports educational efforts aimed at empowering individuals to take control of their health. Public health initiatives and screening programs are a part of preventive healthcare efforts. CRP testing can be integrated into these programs to identify individuals at risk of inflammatory conditions and related diseases. This proactive approach can lead to early interventions, reducing the burden of chronic diseases on healthcare systems.

Increasing Geriatric Population And Associated Chronic Diseases

The increasing geriatric population and the associated prevalence of chronic diseases play a significant role in driving the growth of the global C-reactive protein (CRP) testing market. The global 60+ population is projected to grow from 1 billion in 2020 to 1.4 billion in the coming years. By 2050, this demographic will double to 2.1 billion. Additionally, the number of people aged 80 and older is expected to triple, reaching 426 million by 2050. Aging is associated with changes in the immune system, making older adults more susceptible to inflammation. Chronic low-grade inflammation, known as inflammation, is common in the elderly and contributes to the development of various age-related chronic diseases. CRP testing is a valuable tool to assess and monitor this chronic inflammation, providing insights into disease risk and progression. The geriatric population is more prone to chronic diseases such as cardiovascular diseases, diabetes, osteoarthritis, and certain cancers. CRP testing helps healthcare providers evaluate the inflammatory component of these diseases, aiding in their diagnosis, management, and monitoring. Older adults are at an increased risk of cardiovascular diseases, and inflammation is a key factor in their pathogenesis. CRP testing is used to assess cardiovascular risk and guide treatment decisions, particularly in the elderly population, where preventive measures are crucial. Elderly individuals often have multiple chronic conditions simultaneously. CRP testing provides insights into the overall inflammatory status, helping healthcare providers manage multimorbidity more effectively and make informed treatment choices. Older adults are more susceptible to infections due to age-related changes in the immune system. CRP levels can rise in response to infections, aiding in the assessment and monitoring of infectious diseases, which can have more serious consequences in the elderly. Preventive healthcare in the geriatric population emphasizes early detection and intervention to prevent disease progression and improve quality of life. CRP testing contributes to this approach by detecting inflammation at an early stage, allowing for timely interventions and personalized treatment plans. Geriatric care facilities and long-term care settings often serve individuals with complex health needs. CRP testing is a valuable tool in these settings for monitoring residents' health, identifying potential infections, and managing chronic diseases.

Download Free Sample Report

Key Market Challenges

Non-Specificity of Elevated CRP

The non-specificity of elevated C-reactive protein (CRP) levels poses a challenge to the global CRP testing market primarily because it can lead to uncertainties in diagnosis and treatment decisions. Elevated CRP levels indicate the presence of inflammation, but they do not provide specific information about the underlying cause of inflammation. This lack of specificity can lead to diagnostic confusion, as healthcare providers may need to conduct additional tests to pinpoint the exact condition causing the elevated CRP. As a result, there might be delays in diagnosing the actual underlying disease. The non-specific nature of CRP elevation can lead to situations where CRP testing is ordered excessively or inappropriately, contributing to unnecessary healthcare costs and resource utilization. Healthcare providers may order CRP tests in cases where inflammation is present but not clinically significant, potentially leading to overdiagnosis and overuse of healthcare services.

Varied Reference Ranges

Different laboratories and healthcare facilities may use varying reference ranges for defining normal, elevated, and high CRP levels. This inconsistency can lead to confusion among healthcare providers and patients when interpreting CRP test results. A value that is considered normal in one setting might be categorized as elevated in another, affecting clinical decision-making. Varied reference ranges can create uncertainty about whether a given CRP level is within a normal range or indicative of inflammation. This ambiguity can lead to challenges in diagnosing inflammatory conditions accurately, potentially delaying appropriate treatment and management. Efforts to establish standardized reference ranges for CRP levels can help ensure consistent interpretation across different settings and laboratories. Professional medical organizations can provide guidelines and recommendations for interpreting CRP test results and defining reference ranges based on clinical evidence and consensus.

Influence of External Factors

The influence of external factors on C-reactive protein (CRP) levels can pose challenges to the global CRP testing market, affecting the accuracy, interpretation, and clinical utility of CRP test results. CRP levels can be affected by various external factors, such as smoking, obesity, and medications. These factors can lead to elevated CRP levels even in the absence of significant inflammation. Healthcare providers may misinterpret elevated CRP levels as indicative of inflammation when they are actually driven by external influences. When external factors contribute to elevated CRP levels, healthcare providers may face challenges in distinguishing between true inflammation and non-inflammatory causes of CRP elevation. This complexity can lead to difficulties in accurately diagnosing and managing inflammatory conditions. External factors can lead to false positive or false negative CRP test results. For example, a patient with inflammation might have normal CRP levels due to the influence of certain medications. Conversely, a patient with elevated CRP levels due to non-inflammatory factors might be wrongly considered at risk for inflammation-related conditions. External factors can lead to fluctuations in CRP levels over time, even in the absence of changes in disease status. This inconsistency can make it challenging to monitor disease progression accurately and make informed treatment decisions.

Key Market Trends

Rising Demand for Personalized Medicine

The rising demand for personalized medicine is a significant trend in the global C-reactive protein (CRP) testing market, influencing its growth and application. Personalized medicine aims to tailor medical treatment and interventions to individual patients based on their unique characteristics, including genetic makeup, lifestyle, and biomarker profiles. Personalized medicine relies on biomarkers to guide treatment decisions. CRP testing serves as a valuable biomarker for assessing inflammation, which plays a role in various diseases. Healthcare providers use CRP levels to help determine the most appropriate treatment strategies for individual patients. CRP testing contributes to personalized medicine by assessing an individual's risk for certain diseases, such as cardiovascular diseases. Elevated CRP levels can indicate increased risk, prompting healthcare providers to implement preventive measures and lifestyle interventions tailored to the patient's risk profile. In personalized medicine, ongoing monitoring of disease progression is essential. CRP testing provides a means to monitor the level of inflammation over time, enabling healthcare providers to adjust treatment plans based on changes in CRP levels and disease status. Personalized medicine involves monitoring a patient's response to treatment. CRP testing helps healthcare providers gauge the effectiveness of interventions by tracking changes in inflammation levels. If CRP levels decrease, it may indicate a positive response to treatment.

Segmental Insights

Assay Type Insights

Based on the category of Assay Type, immunoturbidimetric assays segment emerges as the fastest growing segment in the Global C-reactive Protein Testing Market. Immunoturbidimetric assays are highly accurate and precise, making them ideal for clinical applications. Immunoturbidimetric assays are relatively easy to use, making them suitable for use in a variety of settings, including hospitals, clinics, and diagnostic laboratories. Immunoturbidimetric assays are relatively cost-effective, making them a good option for budget-conscious organizations. In immunoturbidimetric assays, the amount of light scattered by a solution is measured to determine the concentration of an analyte. The segment is projected to experience the highest compound annual growth rate (CAGR) from 2023 to 2030.

Detection Range Insight

In 2024, the C-reactive Protein Testing market was dominated by hs-CRP 3 segment segment and is predicted to continue expanding over the coming years. hs-CRP 3 assays are more sensitive than conventional CRP assays, which means they can detect lower levels of CRP. This makes them more useful for assessing the risk of cardiovascular disease. hs-CRP 3 assays are widely accepted by clinicians and are used in many clinical guidelines. This makes them a good option for organizations that want to use a validated assay. hs-CRP 3 assays are relatively cost-effective, making them a good option for budget-conscious organizations.

End-Use Industry Insights

In 2024, the C-reactive Protein Testing market was dominated by hospital segment and is predicted to continue expanding over the coming years. The growth of the hospital segment can be attributed to the growing use of CRP tests in hospitals, especially in developing countries around the world. Due to the increasing prevalence of diseases such as coronavirus, coronary artery disease (CVD), and cancer related infections, the number of hospital admissions has increased, which has led to an increase in the need for CRP test kits.

Download Free Sample Report

Regional Insights

North America has emerged as the largest market in the global C-reactive protein (CRP) testing industry, driven by advanced healthcare infrastructure, a rising prevalence of chronic diseases, strong R&D investment, and increasing adoption of preventive diagnostics. The region, led by the United States and Canada, continues to witness growing demand for CRP testing due to its critical role in diagnosing and monitoring inflammatory conditions, infectious diseases, and cardiovascular disorders. The burden of chronic diseases in North America is one of the key reasons for the region’s dominance in the CRP testing market. The rising incidence of cardiovascular diseases (CVDs), autoimmune disorders, and metabolic conditions has led to increased adoption of CRP testing as a diagnostic and risk assessment tool. The U.S. and Canada report high rates of heart disease, stroke, and hypertension, all of which are linked to chronic inflammation. High-sensitivity CRP (hs-CRP) testing is widely used in assessing cardiovascular risk. Heart disease remains the leading cause of death across men, women, and most racial and ethnic groups. On average, one person dies every 33 seconds due to cardiovascular disease. In 2022, heart disease claimed 702,880 lives, accounting for one in every five deaths. Conditions like rheumatoid arthritis, lupus, and inflammatory bowel disease (IBD) are prevalent in North America, fueling the demand for regular CRP testing to monitor disease progression. With rising obesity rates, North America faces increasing cases of type 2 diabetes, where CRP levels serve as an indicator of systemic inflammation and disease risk.

North America boasts a highly developed healthcare system, ensuring widespread access to advanced diagnostic technologies, including point-of-care (POC) CRP testing, high-sensitivity CRP (hs-CRP) assays, and automated laboratory solutions. The United States has a robust network of hospitals, diagnostic laboratories, and research institutions that actively use CRP testing as part of routine screenings and disease management programs. Reimbursement policies in North America support early disease detection and preventive diagnostics, encouraging higher CRP test adoption.

Recent Developments

• In October 2024, Neuvivo has submitted a New Drug Application (NDA) to the FDA for NP001, an investigational therapy designed to regulate innate immune function in patients with amyotrophic lateral sclerosis (ALS). If approved, NP001 could become the first disease-modifying treatment to restore immune system balance by controlling inflammation associated with ALS.

Key Market Players

• Thermo Fisher Scientific, Inc.
• F. Hoffmann-La Roche Ltd.
• Danaher Corp
• Quest Diagnostics
• Siemens Healthineers AG
• Abbott Laboratories Inc.
• Merck KGaAA
• Zoetis Inc.
• Ortho Clinical Diagnostics
• Getein Biotech, Inc.

In this report, the Global C-reactive Protein Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• C-reactive Protein Testing Market, By Assay Type:

o   Immunoturbidimetric Assay

o   ELISA

o   Chemiluminescence Immunoassay

o   Others

• C-reactive Protein Testing Market, By Detection Range:

o   hs-CRP

o   Conventional CRP

o   cCRP

• C-reactive Protein Testing Market, By Disease Area:

o   Cardiovascular Diseases

o   Cancer

o   Rheumatoid Arthritis

o   Inflammatory Bowel Disease

o   Endometriosis

o   Lupus

o   Others

• C-reactive Protein Testing Market, By End-User:

o   Hospitals & Clinics

o   Laboratories

o   Assisted Living Healthcare Facilities

o   Homecare

o   Others

• C-reactive Protein Testing Market, By region:

o   North America

§  United States

§  Canada

§  Mexico

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Australia

§  Japan

o   Europe

§  Germany

§  France

§  United Kingdom

§  Spain

§  Italy

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global C-reactive Protein Testing Market.

Available Customizations:

Global C-reactive Protein Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global C-reactive Protein Testing Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com